Reporting from ACC 2024 - REDUCE-AMI: No Benefit to Beta Blockers Post-Myocardial Infarction If LVEF is Normal
Use of beta-blockers following myocardial infarction does not provide significant benefit for patients with a normal left ventricular ejection fraction (LVEF), according to results of the REDUCE-AMI trial.
A parallel-group, open-label trial assessing the effect of long-term beta-blocker use, results of the trial, which were presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, suggest long-term beta-blocker use was not associated with a significant reduction in risk of all-cause mortality or new myocardial infarction among patients with an LVEF of 50% or greater.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
